Compared with WT mice, Gstz1 knockout significantly reduced the inhibitory effects of sorafenib treatment in vivo than that in WT mice, as indicated by the increased tumor sizes, number of tumor nodules, and a higher level of alanine aminotransferase (ALT) in serum (Fig. 7B–E). The gene discussed is GSTZ1; the disease is neoplasm.